

Litao An*, Xiaojun Sun, Meng Lv, Jianfeng Zhou, Fengxia Zhu and Hui Zhong

Metal-free oxidative coupling of aminopyridines with nitroolefins to imidazo[1,2-*a*]pyridine in the presence of I₂-TBHP-pyridine

DOI 10.1515/znb-2015-0171

Received October 21, 2015; accepted November 26, 2015

Abstract: A facile metal-free approach to the synthesis of imidazo[1,2-*a*]pyridine was developed through a tandem reaction of Michael addition and oxidative coupling. Iodine-*t*-butyl hydroperoxide-pyridine was found to be a green and efficient catalytic system for this approach.

Keywords: imidazo[1,2-*a*]pyridine; metal free; Michael addition; oxidative coupling.

1 Introduction

Metal-catalyzed coupling reactions have provided powerful tools for the formation of carbon-carbon bonds and carbon-heteroatom bonds to a wide range of compounds in many areas [1-4]. Coupling reactions have been extensively studied to develop innovative and greener approaches. Metal-free coupling is an important and increasingly trendy highlight that has attracted much attention in recent years [5-7]. Although traditional metal-catalyzed coupling reactions have been proven effective in many industrial applications, they are also generating harmful metal waste and much other organic waste. In addition, some metal catalysts are moisture and/or air sensitive. Owing to mild conditions, low cost, and good efficiency, metal-free catalysts could be candidates for many green processes in both academic and industrial research.

Imidazo[1,2-*a*]pyrimidines are important heterocyclic compounds [8]. They are prominent among

nitrogen-containing fused heterocycles and are known for a plethora of biological and pharmacological properties [9], such as antidepressant [10], anticancer, antiviral, antiparasitic, and anti-human immunodeficiency virus activities. Furthermore, they are also the core structure of some currently marketed drugs, such as zolimidine, zolpidem, loproprone, and alpidem. Therefore, much interest has been drawn to develop the imidazo[1,2-*a*]pyridine preparation.

Traditionally, coupling of 2-aminopyridines with α -halocarbonyl compounds provides a practical method to imidazo[1,2-*a*]pyridine [11-13]. This protocol was also extended to similar α -functionalized ketones [14, 15]. Other methods included (i) the condensation of 2-aminopyridines and aromatic ketones [16-18]; (ii) one-pot condensations of 2-aminopyridines, aldehydes, and isonitriles [19-22]; (iii) three-component reactions of 2-aminopyridines, aldehydes, and alkynes [13-25], or oxidative cross-coupling/cyclization between 2-aminopyridines and terminal alkynes [26]; (iv) condensation of 2-aminopyridines with 1,3-dicarbonyl compounds [27, 28]; and (v) condensation of 2-aminopyridines with chalcones [29, 30]. (vi) Moreover, recently, Yan and co-workers have developed a CuBr-catalyzed method for the preparation of imidazo[1,2-*a*]pyridines from aminopyridines and nitroolefins [31]. Subsequently, FeCl₂ [32] and FeCl₃ [33, 34] were developed to promote the construction of imidazo[1,2-*a*]pyridine from in situ-generated or as-prepared nitroolefins. However, there are very few reports on metal-free catalysts for this route [35, 36]. In the former example, the authors found that Bu₄Ni-TBHP (*t*-butyl hydroperoxide) was an efficient catalytic system [35]. In the more recent example, a new protocol was presented in which the cycloaddition of *N*-aminopyridines and β -nitroolefins to substituted pyrazolo[1,5-*a*]pyridines had been developed [36]. Thus, a mild, green protocol for the synthesis of imidazo[1,2-*a*]pyridine is still desirable. Encouraged by the previous reports and as a part of our continuing study on metal-free/catalyst-free reactions in green chemistry [37, 38], we wish to report herein a metal-free I₂-TBHP-pyridine combination mediated by the formation of imidazo[1,2-*a*]pyridine via Michael addition and oxidative coupling.

*Corresponding author: Litao An, Jiangsu Key Laboratory for Chemistry of Low-Dimensional Materials, College of Chemistry and Chemical Engineering, Huaiyin Normal University, Huaian 223300, Jiangsu Province, P.R. China, Tel.: +86 517-83525083, Fax: +86 517-83525663, E-mail: anltao@hotmail.com

Xiaojun Sun, Meng Lv, Jianfeng Zhou, Fengxia Zhu and Hui Zhong: Jiangsu Key Laboratory for Chemistry of Low-Dimensional Materials, College of Chemistry and Chemical Engineering, Huaiyin Normal University, Huaian 223300, Jiangsu Province, P.R. China

2 Results and discussion

To begin with our study, the reaction of 2-aminopyridine and β -nitrostyrene was chosen as a model reaction to screen the conditions (Table 1). The reaction occurred at room temperature, resulting in poor yield (Table 1, entry 1). Even at an elevated temperature, the material could not be consumed completely. Inspired by I_2 -TBHP in the C–N oxidative coupling [29, 39], the catalytic system was also tested for the model reaction. Fortunately, a good yield was achieved (Table 1, entry 2). When a catalytic amount of pyridine was added to the reaction mixture, the material was consumed in shorter time with comparative yield (Table 1, entry 3). When the loading of I_2 was increased to 0.2 equiv, a better yield was given (Table 1, entry 4). Similarly, less TBHP gave poor yield (Table 1, entry 5). It is shown that it may be due to the synergistic effect in the catalytic system of


I_2 -TBHP-Py [40]. However, the model reaction under the optimal condition without any solvent gave a negative result (Table 1, entry 6). Besides these trials, other candidates were also investigated, but they could not lead to better results (Table 1, entries 7–12).

The substrate scope then was investigated under the optimized reaction conditions (Table 2). In most cases, the reaction proceeded smoothly in moderate to good yield. It was observed that some functional groups, such as amino, nitro, halo, and methoxy, were tolerable in the catalytic system. Generally speaking, 2-aminopyridine resulted in better yields than 3-methyl 2-aminopyridine. It was reported that *ortho*-substituted nitroolefins did not give the desired imidazo[1,2-*a*]pyridines in the presence of Bu_4NI -TBHP [35]. It is noteworthy that fairly moderate yields were achieved for *ortho*-substituted nitroolefins under our catalytic system (Table 2, **3e**, **3m**). It was interesting that the catalytic system was effective even at room temperature in some cases (Table 2, **3d–i**, **3k**, **3m**, **3o**). Based on TLC analysis, a reaction at room temperature gave fewer spots than those at elevated temperature in these cases. Finally, the scope was extended to other substrates (Table 3). As for a heterocycle-substituted nitroolefin, it produced a complex mixture (Table 3, entry 1). It was the same when (*E*)-(2-nitroprop-1-en-1-yl)benzene was used instead of β -nitrostyrene (Table 3, entry 2). The reaction of β -nitrostyrene with acetylated 2-aminopyridine did not occur (Table 3, entry 3). It might be due to reduced activity of an amino in the presence of an acetyl group. If the amino was replaced with a benzyl group, only a poor yield could be obtained. It was more interesting that the benzyl was removed in the reaction process (Table 3, entry 4).

We have also attempted to construct new fused thiazoles and imidazoles by this protocol. Structures similar to 2-aminopyridine, such as 2-aminobenzimidazole and 2-aminobenzothiazole, were chosen as candidates (Table 3, entries 5 and 6). However, neither of them took part in the reaction. It was also observed that 4-aminopyridine does not undergo the Michael reaction with β -nitrostyrene under the catalytic condition (Table 3, entry 7). Activated alkene, 2-(2-fluorobenzylidene) malononitrile, which was suggested as a Michael addition acceptor, did not proceed as well in the reaction (Table 3, entry 8). Thus, this method showed good selectivity.


Based on the above results and previous reports [31, 35, 40], a plausible mechanism is put forward (Scheme 1). On the one hand, “outer complex” **4** was formed from pyridine and iodine. In the presence of TBHP, intermediate **5** was generated, which split into two kinds of radicals,

Table 1: Optimization of reaction conditions.^a



Entry	Catalyst	Solvent	Temp. (°C)	Reaction time (h)	Yield ^b (%)
1	I_2	CH_3CN	r. t.	24	36 ^c
2	I_2 -TBHP	CH_3CN	80	20	80 ^d
3	I_2 -TBHP-Py	CH_3CN	80	12	81 ^e
4	I_2 -TBHP-Py	CH_3CN	80	12	90 ^f
5	I_2 -TBHP-Py	CH_3CN	80	12	66 ^{g,c}
6	I_2 -TBHP-Py	Solventless	80	24	16 ^{f,c}
7	TBHP	CH_3CN	r. t.	24	– ^h
8	TBHP	CH_3CN	80	24	– ^h
9	I_2 -Py	CH_3CN	80	12	71 ⁱ
10	TBHP-Py	CH_3CN	80	24	80 ^j
11	I_2 -30 % H_2O_2	CH_3CN	80	12	52 ^k
12	KI-TBHP	CH_3CN	80	17	65 ^l

^aReaction condition: 2-aminopyridine (1.0 mmol), nitroolefin (1.05 mmol), solvent (10 mL), temperature means the oil bath temperature; ^bisolated yields; ^c I_2 (0.2 mmol) was used, and the materials were not consumed completely; ^d I_2 (0.1 mmol) and TBHP (2.0 mmol) were added; ^e I_2 (0.1 mmol), pyridine (0.62 mmol), and TBHP (2.0 mmol) were added; ^f I_2 (0.2 mmol), pyridine (0.62 mmol), and TBHP (2.0 mmol) were added; ^g I_2 (0.2 mmol), pyridine (0.62 mmol), and TBHP (1.0 mmol) were added; ^hno reaction, and TBHP (2.0 mmol) was used; ⁱ I_2 (0.2 mmol) and pyridine (0.62 mmol) were added; ^jTBHP (2.0 mmol) and pyridine (0.62 mmol) were added; ^k30 % H_2O_2 (1 mL) was used; ^lKI (0.2 mmol) and TBHP (2.0 mmol) were added.

Table 2: Synthesis of imidazo[1,2-*a*]pyridines.^a

^aReaction conditions: 2-aminopyridine (1.0 mmol), nitroolefin (1.05 mmol), I₂ (0.2 mmol), pyridine (0.62 mmol), and TBHP (2.0 mmol) were added in CH₃CN (10 mL). The reaction time was 12 h. Temperature means the oil bath temperature. ^bIsolated yields.

6 and **7**. The radicals **6** or **7** resulted in PyHI **8** or TBHP after activating the intermediate **12**, which would be illustrated in the following step. PyHI **8** and HI were oxidized by TBHP to “outer complex” **4**. Thus, the catalytic cycle was achieved.

On the other hand, intermediate **9** was produced from β-nitrostyrene and 2-aminopyridine via Michael addition. The intermediate **9** was oxidized to imine **10**, from which enamine **11** equilibrated. The intermediate **12**, generated by one-electron oxidation, was abstracted of hydrogen by radicals **6** or **7** to intermediate **13**. After intramolecular nucleophilic addition occurred, the final product was obtained by proton elimination of intermediate **14**.

3 Conclusions

In summary, we have successfully developed a metal-free catalytic system for the synthesis of 3-nitro-2-arylimidazo[1,2-*a*]pyridine derivatives. The component in this system shows a synergistic effect for catalysis. It is simple and environmentally benign.

4 Experimental section

All materials were obtained from commercial suppliers and were used without further purification unless

Table 3: The trials on extension of scope under the present catalytic system.


Entry	1	2	Product (yield)	Temp. (°C)
1			Complex mixture	80
2			Complex mixture	100
3			No reaction	100
4			3a (20 %)	100
5			No reaction	100
6			No reaction	100
7			No reaction	100
8			No reaction	100

^aReaction conditions: 2-aminopyridine (1.0 mmol), nitroolefin (1.05 mmol), I₂ (0.2 mmol), pyridine (0.62 mmol), TBHP (2.0 mmol), and CH₃CN (10 mL). Temperature means the oil bath temperature. The reaction time was 12 h. ^bIsolated yields.

otherwise noted. The nitroolefins were prepared by the Henry reaction. All solvents were reagent grade. Flash chromatography was performed with silica gel (200–300 mesh). The nuclear magnetic resonance (NMR) spectra were measured on an AVANCE 400 spectrometer at 400 MHz for ¹H and 100 MHz for ¹³C in CDCl₃ solution with trimethylsilyl as an internal standard. Chemical shifts (δ) are given in parts per million and coupling constants (J) in Hertz. High-resolution mass spectroscopy (HRMS) spectra were recorded on an LTQ-Orbitrap mass spectrometer [(+)-ESI].

4.1 General procedure for the synthesis of imidazo[1,2-*a*]pyridine derivatives

In a 50-mL round-bottomed flask, a mixture of 2-aminopyridine (1 mmol) and nitroolefin (1.05 mmol) was stirred in 10 mL acetonitrile. Then, I₂ (0.2 mmol), TBHP (2 mmol), and pyridine (0.05 mL) were added to the above mixture, and the resulting mixture was allowed to stir under reflux or at room temperature for the specified time (Table 2). The progress of the reaction was monitored by thin-layer chromatography (TLC). After the completion of the reaction, the reaction mixture was cooled to room temperature and poured into saturated sodium bisulfite

**Scheme 1:** Proposed mechanism.

solution (15 mL). After sonication for 10 min, the mixture was extracted with ethyl acetate (3 × 15 mL), followed by drying with anhydrous MgSO₄. After evaporation of the solvent, the residue was purified by flash chromatography to afford the desired product.

4.1.1 3-Nitro-2-phenylimidazo[1,2-*a*]pyridine (3a) [35]

¹H NMR (400 MHz, CDCl₃): δ = 9.53 (d, *J* = 6.9 Hz, 1H), 7.91–7.92 (m, 2H), 7.86 (d, *J* = 8 Hz, 1H), 7.67 (t, *J* = 7.9 Hz, 1H), 7.52–7.53 (m, 3H), 7.28–7.32 (m, 1H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 150.3, 145.2, 131.9, 130.8, 130.2, 130.1, 128.2, 128.2, 118.3, 116.5. – HRMS [(+)-ESI]: *m/z* = 240.0776 (calcd. 240.0773 for C₁₃H₁₀N₃O₂, [M+H]⁺).

4.1.2 2-(4-Methoxyphenyl)-3-nitroimidazo[1,2-*a*]pyridine (3b) [31]

¹H NMR (400 MHz, CDCl₃): δ = 9.50 (d, *J* = 6.8 Hz, 1H), 7.95 (d, *J* = 8.5 Hz, 2H), 7.81 (d, *J* = 8.8 Hz, 1H), 7.64 (t, *J* = 8 Hz, 1H), 7.24 (d, *J* = 6.8 Hz, 1H), 7.02 (d, *J* = 8.5 Hz, 2H), 3.89 (s, 3H) ppm. – HRMS [(+)-ESI]: *m/z* = 270.0871 (calcd. 270.0879 for C₁₄H₁₂N₃O₃, [M+H]⁺).

4.1.3 3-Nitro-2-*p*-tolylimidazo[1,2-*a*]pyridine (3c) [35]

¹H NMR (400 MHz, CDCl₃): δ = 9.51 (d, *J* = 6.9 Hz, 1H), 7.83 (d, *J* = 8.0 Hz, 3H), 7.64 (t, *J* = 7.9 Hz, 1H), 7.31 (d, *J* = 8 Hz, 2H), 7.22–7.27 (m, 1H), 2.44 (s, 3H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 150.4, 145.2, 140.5, 130.7, 130.0, 129.0, 128.9, 128.2, 118.2, 116.3, 21.5 ppm. – HRMS [(+)-ESI]: *m/z* = 276.0740 (calcd. 276.0749 for C₁₄H₁₁N₃O₂Na, [M+Na]⁺).

4.1.4 2-(Benzo[*d*][1,3]dioxol-5-yl)-3-nitroimidazo[1,2-*a*]pyridine (3d) [41]

¹H NMR (400 MHz, CDCl₃): δ = 9.50 (d, *J* = 6.8 Hz, 1H), 7.80 (d, *J* = 8.9 Hz, 1H), 7.64 (t, *J* = 7.9 Hz, 1H), 7.52 (dd, *J* = 8.1, 1.4 Hz, 1H), 7.43 (d, *J* = 1.2 Hz, 1H), 7.24–7.27 (m, 1H), 6.93 (d, *J* = 8.1 Hz, 1H), 6.05 (s, 1H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 150.0, 149.5, 147.5, 145.1, 131.0, 128.3, 125.5, 125.1, 118.2, 116.3, 110.5, 108.2, 101.5 ppm. – HRMS [(+)-ESI]: *m/z* = 284.0670 (calcd. 284.0671 for C₁₄H₁₀N₃O₄, [M+H]⁺).

4.1.5 2-(2-Fluorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3e)

¹H NMR (400 MHz, CDCl₃): δ = 9.47 (d, *J* = 7.0 Hz, 1H), 7.85 (d, *J* = 8.9 Hz, 1H), 7.63–7.70 (m, 2H), 7.48–7.53 (m, 1H), 7.28–7.32 (m, 2H), 7.21 (t, *J* = 9.2 Hz, 1H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 161.8, 159.3, 145.2, 144.3, 131.9, 131.8, 131.1, 131.1, 130.7, 127.8, 124.2, 124.2, 121.0, 120.8, 118.4, 116.7, 115.9, 115.7 ppm. – HRMS [(+)-ESI]: *m/z* = 280.0496 (calcd. 280.0498 for C₁₃H₈FN₃O₂Na, [M+Na]⁺).

4.1.6 2-(3-Bromophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3f) [31]

¹H NMR (400 MHz, CDCl₃): δ = 9.42 (d, *J* = 7.2 Hz, 1H), 8.01 (s, 1H), 7.81 (t, *J* = 8.4 Hz, 2H), 7.57–7.66 (m, 2H), 7.24–7.35 (m, 2H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 148.2, 145.0, 133.9, 133.0, 132.8, 131.1, 129.6, 128.8, 128.0, 122.0, 118.3, 116.8 ppm. – HRMS [(+)-ESI]: *m/z* = 339.9702 (calcd. 339.9698 for C₁₃H₈BrN₃O₂Na, [M+Na]⁺).

4.1.7 2-(4-Bromophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3g) [41]

¹H NMR (400 MHz, CDCl₃): δ = 9.5 (d, *J* = 7.2 Hz, 1H), 7.80–7.85 (m, 3H), 7.63–7.69 (m, 3H), 7.27–7.32 (m, 1H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 149.1, 145.2, 131.7, 131.4, 131.1, 130.8, 128.2, 124.9, 118.4, 116.7 ppm. – HRMS [(+)-ESI]: *m/z* = 339.9695 (calcd. 339.9698 for C₁₃H₈BrN₃O₂Na, [M+Na]⁺).

4.1.8 2-(4-Chlorophenyl)-3-nitroimidazo[1,2-*a*]pyridine (3h) [31]

¹H NMR (400 MHz, DMSO): δ = 9.42 (d, *J* = 6.8 Hz, 1H), 7.97 (d, *J* = 8.8, 1H), 7.82–7.88 (m, 3H), 7.59 (d, *J* = 8 Hz, 2H), 7.49 (t, *J* = 7.2 Hz, 1H). – ¹³C NMR (100 MHz, DMSO): δ = 148.3, 145.2, 135.1, 132.4, 132.2, 131.6, 128.9, 128.5, 118.3, 117.7. – HRMS [(+)-ESI]: *m/z* = 274.0387 (calcd. 274.0383 for C₁₃H₉ClN₃O₂, [M+H]⁺).

4.1.9 8-Methyl-3-nitro-2-phenylimidazo[1,2-*a*]pyridine (3i) [31]

¹H NMR (400 MHz, CDCl₃): δ = 9.35 (d, *J* = 6.8 Hz, 1H), 7.91 (d, *J* = 3.6 Hz, 2H), 7.48–7.50 (m, 3H), 7.43 (d, *J* = 6.8 Hz, 1H), 7.16 (t, *J* = 8 Hz, 1H), 2.73 (s, 3H) ppm. – ¹³C NMR

(100 MHz, CDCl₃): δ = 149.7, 145.2, 132.3, 130.1, 130.0, 129.9, 128.7, 128.1, 125.9, 116.5, 77.4, 77.1, 76.7, 16.6 ppm. – HRMS [(+)-ESI]: m/z = 254.0933 (calcd. 254.0930 for C₁₄H₁₂N₃O₂, [M+H]⁺).

4.1.10 2-(4-Methoxyphenyl)-8-methyl-3-nitroimidazo[1,2-*a*]pyridine (3j)

¹H NMR (400 MHz, CDCl₃): δ = 9.32 (d, *J* = 6.0 Hz, 1H), 7.94 (d, *J* = 8.6 Hz, 2H), 7.40 (d, *J* = 6.9 Hz, 1H), 7.11 (t, *J* = 6.9 Hz, 1H), 7.00 (d, *J* = 8.4 Hz, 2H), 3.87 (s, 3H), 2.69 (s, 3H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 161.22, 149.59, 145.21, 131.89, 129.85, 128.32, 125.97, 124.48, 116.11, 113.59, 55.37, 16.52 ppm. – HRMS [(+)-ESI]: m/z = 306.0857 (calcd. 306.0855 for C₁₅H₁₃N₃O₃Na, [M+Na]⁺).

4.1.11 8-Methyl-3-nitro-2-*p*-tolylimidazo[1,2-*a*]pyridine (3k) [31]

¹H NMR (400 MHz, CDCl₃): δ = 9.33 (d, *J* = 6.9 Hz, 1H), 7.83 (d, *J* = 7.9 Hz, 2H), 7.40 (d, *J* = 7.0 Hz, 1H), 7.30 (d, *J* = 7.8 Hz, 2H), 7.13 (t, *J* = 7.0 Hz, 1H), 2.70 (s, 3H), 2.43 (s, 3H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 149.8, 145.2, 140.3, 130.1, 129.8, 129.3, 128.8, 128.5, 125.9, 116.3, 21.5, 16.6 ppm. – HRMS [(+)-ESI]: m/z = 268.1082 (calcd. 268.1086 for C₁₅H₁₄N₃O₂, [M+H]⁺).

4.1.12 2-(Benzo[*d*][1,3]dioxol-5-yl)-8-methyl-3-nitroimidazo[1,2-*a*]pyridine (3l)

¹H NMR (400 MHz, CDCl₃): δ = 9.35 (d, *J* = 6.9 Hz, 1H), 7.51–7.58 (dd, *J* = 6.4 Hz, 1.6 Hz, 1H), 7.43 (d, *J* = 1.6 Hz, 2H), 7.15 (t, *J* = 7.1 Hz, 1H), 6.93 (d, *J* = 8.1 Hz, 1H), 6.04 (s, 1H), 2.71 (s, 3H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 149.4, 149.3, 147.5, 145.1, 129.9, 128.4, 125.9, 125.1, 116.3, 110.6, 108.2, 101.5, 16.6 ppm. – HRMS [(+)-ESI]: m/z = 320.0626 (calcd. 320.0647 for C₁₅H₁₁N₃O₄Na, [M+Na]⁺).

4.1.13 2-(2-Fluorophenyl)-8-methyl-3-nitroimidazo[1,2-*a*]pyridine (3m)

¹H NMR (400 MHz, CDCl₃): δ = 9.36 (d, *J* = 6.8 Hz, 1H), 7.66–7.70 (m, 1H), 7.45–7.53 (m, 2H), 7.28–7.32 (m, 1H), 7.18–7.23 (m, 2H), 2.74 (s, 3H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 161.9, 159.4, 145.3, 143.8, 131.8, 131.7, 131.2, 131.2, 129.7, 128.7, 125.5, 124.2, 124.2, 121.2, 121.1, 116.6, 115.9, 115.6, 16.7 ppm. – HRMS [(+)-ESI]: m/z = 294.0651 (calcd. 294.0655 for C₁₄H₁₀FN₃O₂Na, [M+Na]⁺).

4.1.14 2-(4-Bromophenyl)-8-methyl-3-nitroimidazo[1,2-*a*]pyridine (3n)

¹H NMR (400 MHz, CDCl₃): δ = 9.37 (d, *J* = 6.9 Hz, 1H), 7.82 (d, *J* = 8.4 Hz, 1H), 7.65 (d, *J* = 8.4 Hz, 1H), 7.47 (d, *J* = 7.0 Hz, 1H), 7.20 (t, *J* = 7.0 Hz, 1H), 2.73 (s, 2H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 148.5, 145.2, 131.8, 131.4, 131.1, 130.1, 128.7, 125.9, 124.6, 116.7, 16.6 ppm. – HRMS [(+)-ESI]: m/z = 332.0016 (calcd. 332.0029 for C₁₄H₁₁BrN₃O₂, [M+H]⁺).

4.1.15 2-(4-Chlorophenyl)-8-methyl-3-nitroimidazo[1,2-*a*]pyridine (3o)

¹H NMR (400 MHz, CDCl₃): δ = 9.36 (d, *J* = 6.9 Hz, 1H), 7.88 (d, *J* = 8.4 Hz, 2H), 7.47 (t, *J* = 7.2 Hz, 3H), 7.19 (t, *J* = 7.0 Hz, 1H), 2.72 (s, 3H) ppm. – ¹³C NMR (100 MHz, CDCl₃): δ = 148.5, 145.2, 136.2, 131.6, 130.7, 130.1, 128.7, 128.4, 125.9, 116.7, 16.6 ppm. – HRMS [(+)-ESI]: m/z = 288.0530 (calcd. 288.0540 for C₁₄H₁₁ClN₃O₂, [M+H]⁺).

5 Supporting Information

General experimental information, spectroscopic data, and spectra of compounds **3a–3o** are summarized as Supporting Information available online (DOI: 10.1515/znb-2015-0171).

Acknowledgments: We are grateful to the National Natural Science Foundation of China (21375044), University Natural Science Foundation of Jiangsu Province (12KJD150002), and Administration of Science & Technology of Huaian City (HAG2013011) for financial support.

References

- [1] Z. H. Shao, H. B. Zhang, *Chem. Soc. Rev.* **2012**, *41*, 560.
- [2] C. F. Lee, Y. C. Liu, S. S. Badsara, *Chem.-Asian J.* **2014**, *9*, 706.
- [3] Q. Xiao, Y. Zhang, J. B. Wang, *Acc. Chem. Res.* **2013**, *46*, 236.
- [4] A. Bhunia, S. R. Yetra, A. T. Biju, *Chem. Soc. Rev.* **2012**, *41*, 3140.
- [5] J. J. Mousseau, A. B. Charette, *Acc. Chem. Res.* **2013**, *46*, 412.
- [6] R. A. D. Arancon, C. S. K. Lin, C. Vargas, R. Luque, *Org. Biomol. Chem.* **2014**, *12*, 10.
- [7] R. Samanta, K. Matcha, A. P. Antonchick, *Eur. J. Org. Chem.* **2013**, *2013*, 5769.
- [8] F. Couty, G. Evano, in *Comprehensive Heterocyclic Chemistry III* (Eds. A. R. Katritzky, C. A. Ramsden, E. F. V. Scriven, R. J. K. Taylor), Elsevier, Oxford, UK, **2008**, p. 409.
- [9] C. Enguehard-Gueiffier, A. Gueiffier, *Mini-Rev. Med. Chem.* Oxford, UK, **2007**, *7*, 888.

- [10] M. H. Wiegand, *Drugs* **2008**, *68*, 2411.
- [11] Y. Vara, E. Aldaba, A. Arrieta, J. L. Pizarro, M. I. Arriortua, F. P. Cossio, *Org. Biomol. Chem.* **2008**, *6*, 1763.
- [12] S. El Kazzouli, S. Berteina-Raboin, A. Mouaddib, G. Guillaumet, *Lett. Org. Chem.* **2012**, *9*, 118.
- [13] M. Adib, A. Mohamadi, E. Sheikhi, S. Ansari, H. R. Bijanzadeh, *Synlett* **2010**, 1606.
- [14] J. S. Yadav, B. V. S. Reddy, Y. G. Rao, M. Srinivas, A. V. Narsaiah, *Tetrahedron Lett.* **2007**, *48*, 7717.
- [15] C. M. Yu, X. Chen, R. Wu, G. H. Yang, J. Y. Shi, L. L. Pan, *Eur. J. Org. Chem.* **2014**, 2014, 2037.
- [16] A. J. Stasyuk, M. Banasiewicz, M. K. Cyranski, D. T. Gryko, *J. Org. Chem.* **2012**, *77*, 5552.
- [17] K. Pericherla, P. Kaswan, P. Khedar, B. Khungar, K. Parang, A. Kumar, *RSC Adv.* **2013**, *3*, 18923.
- [18] D. C. Mohan, R. R. Donthiri, S. N. Rao, S. Adimurthy, *Adv. Synth. Catal.* **2013**, *355*, 2217.
- [19] M. Adib, M. Mahdavi, M. A. Noghani, P. Mirzaei, *Tetrahedron Lett.* **2007**, *48*, 7263.
- [20] B. Maiti, K. Chanda, M. Selvaraju, C. C. Tseng, C. M. Sun, *ACS Comb. Sci.* **2013**, *15*, 291.
- [21] A. H. Shinde, M. Srilaxmi, B. Satpathi, D. S. Sharada, *Tetrahedron Lett.* **2014**, *55*, 5915.
- [22] A. Maleki, S. Javanshir, M. Naimabadi, *RSC Adv.* **2014**, *4*, 30229.
- [23] J. B. Bharate, S. K. Guru, S. K. Jain, S. Meena, P. P. Singh, S. Bhushan, B. Singh, S. B. Bharate, R. A. Vishwakarma, *RSC Adv.* **2013**, *3*, 20869.
- [24] S. K. Guchhait, A. L. Chandgude, G. Priyadarshani, *J. Org. Chem.* **2012**, *77*, 4438.
- [25] T. Palani, K. Park, M. R. Kumar, H. M. Jung, S. Lee, *Eur. J. Org. Chem.* **2012**, 5038.
- [26] C. He, J. Hao, H. Xu, Y. Mo, H. Liu, J. Han, A. Lei, *Chem. Commun.* **2012**, *48*, 11073.
- [27] L. Ma, X. Wang, W. Yu, B. Han, *Chem. Commun.* **2011**, *47*, 11333.
- [28] X. Wang, L. Ma, W. Yu, *Synthesis* **2011**, *43*, 2445.
- [29] Y. F. Zhang, Z. K. Chen, W. L. Wu, Y. H. Zhang, W. P. Su, *J. Org. Chem.* **2013**, *78*, 12494.
- [30] K. Monir, A. K. Bagdi, S. Mishra, A. Majee, A. Hajra, *Adv. Synth. Catal.* **2014**, *356*, 1105.
- [31] R. -L. Yan, H. Yan, C. Ma, Z. -Y. Ren, X. -A. Gao, G. -S. Huang, Y. -M. Liang, *J. Org. Chem.* **2012**, *77*, 2024.
- [32] H. Yan, S. Yang, X. Gao, K. Zhou, C. Ma, R. Yan, G. Huang, *Synlett* **2012**, *23*, 2961.
- [33] H. Yan, Y. L. Wang, C. M. Pan, H. Zhang, S. Z. Yang, X. Y. Ren, J. Li, G. S. Huang, *Eur. J. Org. Chem.* **2014**, 2014, 2754.
- [34] S. Santra, A. K. Bagdi, A. Majee, A. Hajra, *Adv. Synth. Catal.* **2013**, *355*, 1065.
- [35] X. S. Xu, P. Z. Hu, W. B. Yu, G. Hong, Y. C. Tang, M. W. Fang, X. Q. Li, *Synlett* **2014**, *25*, 718.
- [36] C. Ravi, D. Chandra Mohan, N. Naresh Kumar Reddy, S. Adimurthy, *RSC Adv.* **2015**, *5*, 42961.
- [37] D. P. Li, G. L. Zhang, L. T. An, J. P. Zou, W. Zhang, *Green Chem.* **2011**, *13*, 594.
- [38] L. T. An, F. Q. Ding, J. P. Zou, *Dyes Pigm.* **2008**, *77*, 478.
- [39] X. Liu, G. Q. Yu, J. H. Li, D. Wang, Y. X. Chen, K. Q. Shi, B. H. Chen, *Synlett* **2013**, *24*, 1588.
- [40] J. T. Zhang, Z. T. Wang, Y. Wang, C. F. Wan, X. Q. Zheng, Z. Y. Wang, *Green Chem.* **2009**, *11*, 1973.
- [41] H. Yan, R. Yan, S. Yang, X. Gao, Y. Wang, G. Huang, Y. Liang, *Chem.-Asian J.* **2012**, *7*, 2028.

Graphical synopsis

Litao An, Xiaojun Sun, Meng Lv,
Jianfeng Zhou, Fengxia Zhu and
Hui Zhong

**Metal-free oxidative coupling of
aminopyridines with nitroolefins to
imidazo[1,2-*a*]pyridine in the presence
of I₂-TBHP-pyridine**

DOI 10.1515/znb-2015-0171

Z. Naturforsch. 2016; x(x)b: xxx-xxx

